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Abstract
Stress-inducible phosphoprotein-1 (STI1) levels are increased in the brain following
ischemia. STI1 is a co-chaperone for Hsp70/Hsp90 modulating protein folding. STI1 can also
be secreted by a number of cells and function to activate extracellular signalling by the prion
protein (PrPC) and type-I bone morphogenetic protein receptor ALK2. However, the
mechanisms by which STI1 can protect neurons against ischemia are currently unknown. A
caspase-3 reporter mouse line was used to evaluate the consequences of increased
extracellular STI1 levels. Neurons were treated with recombinant STI1 and specific
agonists/antagonists for PrPC, α7nAChR, and ALK2 prior to oxygen-glucose deprivation
(OGD). STI1 treatment significantly decreased apoptosis and cell death in neurons submitted
to OGD in a manner dependent on PrPC, α7nAChR, and ALK2. Activation of both the
α7nAChR and ALK2 receptor were effective at decreasing neuronal death in response to
ischemia, while BMP-4 treatment post-OGD also decreased neuronal death, suggesting that
α7nAChR and ALK2 receptor may be novel targets for preventing death of neurons after
ischemia.
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1

Introduction and Literature Review

1.1 Stroke
Stroke is currently the third leading cause of death in Canada. Fifty thousand
Canadians suffer from stroke each year, resulting in one stroke every ten minutes. With
315,000 Canadians currently living with the effects of stroke, its societal burden is
estimated to be $3.6 billion annually (Statistics Canada, 2012).
Stroke occurs when blood flow towards the brain is disturbed. When blood flow is
obstructed or reduced within a blood vessel that supplies the brain, the brain tissue
downstream of the occlusion becomes deprived of oxygen and glucose. Deprivation of
these essential nutrients gives rise to a rapidly expanding region of irreversible necrotic
death. Within the tissue surrounding the perimeter of the area of necrosis, known as the
penumbra, resides cells that receives limited blood flow. Unlike the necrotic center, the
penumbra is an area in which damage due to ischemia is not entirely irreversible, but the
cells are pushed towards apoptosis due to an array of insults such as rising levels of
reactive oxygen species, depletion of cellular ATP, glutamate toxicity, and increased
intracellular calcium (Lau et al., 2010, Lakhan et al., 2009, MacDonald et al., 2006).
Neurons are quickly lost during stroke and permanent neurological damage, or even
death, can occur within just minutes of oxygen deprivation. Studies have shown that for
every minute of delay in treating stroke patients, the average brain loses 1.9 million
neurons, 13.8 billion synapses, and 12 km of axonal fibers (Saver, 2006). To put this into
perspective, for every 60 minutes of untreated stroke progression, the patient loses as
many neurons in their brain as they normally would in nearly four years of aging (Saver
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et al., 2006). This further emphasizes the importance of a rapid treatment response for
minimizing neurological damage due to ischemia.

1.1.1

Types of Stroke
There are two types of stroke: ischemic stroke and haemorrhagic stroke. In

ischemic stroke, a clot forms within the arteries that supply blood to the brain (Andersen
et al., 2009). When formed elsewhere in the body, the clot may break off and travel
towards the brain, arrest in a narrow artery, and block any downstream blood flow.
Treatment for ischemic stroke typically involves the intravenous administration of tissue
plasminogen activators that break down blood clots in order to re-introduce blood flow
downstream of the affected areas (Lansberg et al., 2012). Intra-arterial thrombolysis and
mechanical clot removal have also been used. This involves using a catheter entering
from the upper thigh, extending into the arteries of the brain, which allows a more direct
delivery of antithrombolytics (Andersen et al., 2009). When tissue plasminogen
activators are not readily available, an antiplatelet medicine such as aspirin can be used to
slow or stop platelets from aggregating and forming blood clots (Andersen et al., 2009).
Lastly, anticoagulants can also be prescribed to decrease blood clot formation (Lansberg
et al., 2012).
In contrast, haemorrhagic stroke involves a weakened vessel that ruptures and
damages the surrounding areas due to both blood loss and increased pressure (Andersen
et al., 2009). Unlike ischemic stroke, the use of antithrombolytics would exacerbate
haemorrhagic stroke damage, by making the bleeding worse. At times, surgical
procedures must be administered to locate and stop the source of blood loss using
procedures such as aneurysm clipping, coil embolization, and arteriovenous
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malformation repair (Andersen et al., 2009, NHLBI, 2014). Although accounting for only
about 15% of all strokes, intra-cerebral haemorrhage has the highest morbidity and
mortality rates amongst all stroke subtypes (Broderick et al., 2007).

1.1.2

Risk Factors and Current Treatments for Ischemic Stroke
Risk factors for stroke include diabetes, high blood pressure, and old age

(Bousser, 2012). After the age of 55, the risk of stroke doubles every 10 years (Hinkle et
al., 2007). Women have been found to have poorer outcomes from stroke than men, due
to their greater longevity (Statistics Canada, 2012). Despite stroke and stroke treatments
being studied extensively over the past two decades, patients are still limited to a single
approved treatment: intra-venous thrombolytic therapy (Lansberg et al., 2012). To make
matters worse, recent studies have shown that intra-venous thrombolytic therapy is only
effective within 4 hours of the stroke (6 hours if given intra-arterially), and after this time
its efficacy declines significantly (Lansberg et al., 2012). The limited therapeutic
window, coupled by the lack of treatment options, has called attention to the need for
novel therapies that aim to reduce cell death or promote survival following ischemia.

1.1.3

Neurotoxicity during Stroke
There are many factors that contribute to neurotoxicity following ischemic stroke.

During ischemia, disturbances in cellular homeostasis such as ion shifts, excessive
calcium influx, dysregulation of glutamate receptors, and ATP-depletion have been
extensively studied (Lau et al., 2010, MacDonald et al., 2006).
In neurons, calcium is a key regulator in numerous signalling and regulatory
processes. Dysregulation of calcium can occur as a result of increased calcium influx and
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excess intracellular calcium (Berridge, 1998). Thus, both intracellular and extracellular
sources of calcium are tightly regulated. In basal conditions, the osmotic gradient (ratio
of extracellular to intracellular calcium is 10,000:1) and the electrical gradient (negative
on the intracellular side) creates a great potential for calcium influx (Brini et al., 2014).
This electrochemical gradient is upheld by the active Ca2+-2H+ ion transporter and 3Na+Ca2+ exchanger on the cell membrane (Brini et al., 2014). Normally, signal transduction
begins with presynaptic glutamate release, activation of AMPA and NMDA receptors,
sodium influx, postsynaptic depolarization, and calcium influx via calcium-permeable
channels (Brini et al., 2014). Termination of the glutamate/calcium transients occurs via
glutamate reuptake, conversion of glutamate to glutamine/lactate via glial cells, or
activation of potassium channels that result in hyperpolarization of the membrane
(Attwell et al., 1994, Magistretti et al., 1996, Kennedy, 1989). The endoplasmic reticulum
(ER) also stores calcium concentrations equal to the extracellular environment, serving as
a source of calcium that is activated by the phospholipase-C-IP3 signalling pathway
(Irvin, 1986). Although the extracellular environment has 10,000 times higher calcium
concentrations than intracellular environments, almost all of the intracellular calcium is
bound to calcium binding proteins or stored in the ER and mitochondria (Kristian et al,
1998). This intracellular source of calcium is also believed to be a contributor to calciumrelated cell damage during ischemia excitotoxicity (Paschen, 1996)
During ischemia, dysregulation of ion channels such as voltage-gated calcium
channels and NMDA receptors leads to excess calcium influx resulting in neuronal
excitotoxicity (Choi, 1992, Kristian et al., 1998). Within a minute, concentration of
extracellular calcium drops by 90%, indicating that almost all extracellular calcium is
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now intracellular (Kristian et al., 1994). This effect is worse in hippocampal neurons as
CA1 cells have a higher density of NMDA receptors compared to the rest of cortex
(Silver et al., 1992). Calcium from intracellular organelles can also contribute to
excitotoxicity (Kristian et al., 1998). Excess accumulation of intracellular calcium leads
to glutamate toxicity, increase in reactive oxygen species (ROS; such as ·O2−, H2O2, and
·OH), peroxynitrate generation, and degradation of cytoskeletal proteins (Choi et al.,
1988, Tymianski et al., 1996, Siesjo, 1981, Eimerl et al., 1994,). Following
excitotoxicity, many protein kinases and phosphatases are activated or inactivated
aberrantly, and fragmentation of DNA ultimately results in cell death (Hossmann, 1993,
Wieloch et al., 1996).
The mitochondria have been shown to modulate calcium homeostasis by serving
as a sink for transient increases in intracellular calcium (Nicholls, 1985). However,
during glutamate toxicity, the mitochondria increase the production of ROS that
deteriorates the inner mitochondrial membrane (Dykens et al., 1994, Dugan et al., 1995).
Briefly, the electron transport chain in mitochondria relies on a large electrochemical
gradient of H+ established across the inner mitochondrial membrane. In basal conditions,
the membrane is impermeable to H+. However, studies have shown that exposure of
mitochondria to excess calcium and oxidative stress leads to osmotic swelling of the
organelle and release of intramitochondrial components (Gunter et al., 1990, 1994). As a
result, ATP production is stopped due to the breakdown of the electron transport chain.
Dysfunction of the mitochondria as a result of glutamate toxicity and mitochondrial
membrane depolarization is the primary event that leads to cell death (Schinder et al.,
1996, Richter, 1993).
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One of the key regulators of calcium homeostasis is calcium binding proteins.
Interestingly, studies have shown that the expression of calcium binding proteins in
neurons is correlated to resistance against excitotoxicity (Rami et al., 1992, Freund et al.,
1990). In fact, the level of calcium binding proteins decreases during aging, as well as in
Alzheimer’s disease and Parkinson’s disease, which may contribute to cognitive decline
(Thibault et al., 2007, Iacopino et al., 1990). Since the major risk factor for stroke is
aging, the decline in calcium binding protein expression may be a contributing factor as
well.

1.1.4

Recent Pharmacological Approaches
Recent cellular and molecular studies have reported treatments that offer

neuroprotection in rodent models (Tymianski et al., 2010). However, these candidate
neuroprotectants have not been successfully translated into the clinic as treatments for
patients. One significant barrier that needs to be overcome at the clinical trials phase of
candidate drugs development is lack of tools and biomarkers to assess the relationship
between brain damage due to ischemia and clinical outcome (Tymianski et al. 2010).
Unlike myocardial infarctions, which have a straightforward relationship between
myocardial infarct size and myocardial function, it is much more difficult to establish and
evaluate the same relationship in stroke (Cerqueira et al., 1991).
The majority of studies conducted for stroke treatments have been focused on the
signalling mechanisms of regulating neuronal cell death during ischemia and how to
decrease/prevent activation of these pathways in order to increase cell viability
(Tymianski et al. 2010). A recent study found that treatment of hippocampal neurons
with apoaequorin, a calcium binding protein isolated from jellyfish, protects against
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oxygen-glucose deprivation (OGD), which models ischemia, via up-regulation of the
anti-inflammatory cytokine interleukin-10 (Detert et al., 2013). Another study found that
treatment of hippocampal neurons in vitro with melatonin also protected against OGD in
manner dependent on the alpha-7 nicotinic acetylcholine receptor (α7nAChR) (Parada et
al., 2014). Our laboratory has discovered a potential mechanism involving the prion
protein (PrPC) that specifically capitalizes on an endogenous homeostatic response that
plays a critical role during neuronal injury (Beraldo et al., 2013). We anticipate that
understanding the brain’s defense mechanisms during ischemia could help to reveal new
ways to interfere with neuronal death and improve outcomes of stroke patients in the
future.

1.2 Prion Protein
1.2.1

Roles of the Prion Protein in the Nervous System
The prion protein PrPC is a glycosylphosphatidylinositol (GPI)-anchored protein

found abundantly throughout the brain (Sales et al., 1998) and to a lesser degree in select
non-neuronal tissues such as lymphoid tissues, cardiac muscle, and gastrointestinal
mesenteric ganglion cells (Brown et al., 2000, see Table 1). PrPC was first identified from
scrapie-infected hamster brain tissue (Bolton et al., 1984). Coded by the Pnrp gene, the
C-terminal of the PrPC hosts a globular domain (consisting of three alpha-helices and
antiparallel beta-pleated sheets) and the N-terminal hosts a random coil sequence, both of
approximately 100 amino acids in length (Zahn et al., 2000).
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Table 1: Overview of the expression of PrPC in mice and humans
Species

Tissue

Cell type/location

Reference

Mouse

Brain

Neurons – Intracellular

Piccardo et al., 1990

Neuronal processes

Ford et al., 2002b

Spinal cord

Neurons

Ford et al., 2002a

Intestine

Submucosa

Manson et al., 1992

Bone marrow

Hematopoietic stem cells

Kubosaki et al., 2001

Brain

Hippocampus – Presynaptic

Fournier et al., 2000

Cerebellum

Laine et al., 2001

Lymphocytes, monocytes, T-

Durig et al., 2000

Human

Blood

cells, NK cells, B cells
Both

Brain

Neurons - Cortex

Piccardo et al., 1990

Muscle

Subsynaptic sarcoplasm

Gohel et al., 1999
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More than two decades ago, a PrPC-knockout mouse named Pnrp0/0 was produced
to study the functions of PrPC (Bueler et al., 1992). Since then, several PrPC-knockout
mouse lines have been generated. Initial studies of Pnrp0/0 mice showed no observable
morphological differences in the brain, skeletal muscles, and visceral organs, nor any
behavioural/learning deficiencies (Bueler et al., 1992). However, later studies have found
that mice without PrPC expression demonstrate increased locomotor activity when placed
in a novel environment and reduced levels of anxiety during stress (Roesler et al., 1999,
Nico et al., 2005), suggesting that PrPC may play a role in behavioural responses during
stress.
PrPC has also been suggested to play a role in learning. PrPC-null mice
demonstrate normal short-term and long-term memory at 3 months of age, but display
memory impairments at 9 months (Coitinho et al., 2003). Furthermore, pharmacological
antagonism of PrPC leads to impairments of memory in old rats as well (Coitinho et al.,
2003). One of the ligands of PrPC, which will be discussed below in greater detail, is
stress-inducible phosphoprotein-1 (STI1). Interestingly, binding of STI1 to PrPC increases
short-term memory retention and long-term memory consolidation by acting on the CA1
region of the hippocampus (Coitinho et al., 2007), suggesting that the interaction between
STI1 and PrPC may play an endogenous role in learning and memory. The functional
roles of STI1 and PrPC will be discussed in greater detail in the next section.
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1.2.2

Diseases Involving the Prion Protein
Prion diseases, such as Creutzfeldt-Jakob disease in humans and bovine

spongiform encephalopathy (mad cow disease) in other mammals, are identified by
protein aggregation and cellular degeneration in the brain (Prusiner et al., 1998). In prion
diseases, PrPC undergoes a conformational change of its protein structure into PrPSC,
resulting in a fatal and incurable neuronal disease in mammals that leads to death within
few months following diagnosis (Prusiner et al., 1998). The misfolded prions cause
transmissible spongiform encephalopathies by acting as self-replicating infectious agents
(Knight et al., 2004). Both PrPC and PrPSC share the same amino acid sequences coded by
the Prnp gene, suggesting that the different functions between the two are due to posttranslational modifications (Basler et al., 1996). The conformational change from alphahelix to beta-sheets also explains the ability of PrPSC to form and accumulate as compact
aggregates in the brain (Baldwin et al., 1994). Interestingly, studies have shown that
when PrPSC-infected tissue is grafted into a PrPC-knockout mouse, the host tissue is not
affected by PrPSC, suggesting that the development of the prion disease requires
misfolding of the endogenous protein (Brandner et al., 1996).
The progression of prion diseases may also be related to the loss of the
neuroprotective functions off the endogenous PrPC (Linden et al., 2008). Studies have
suggested that the loss of resistance to oxidative stress due the lack of PrPC plays a vital
role in the pathogenesis of prion diseases (Giese et al., 2001). Although the pathology of
prion disease has been extensively studied, less is known about the endogenous roles of
the PrPC.
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PrPC has also been identified to play a role in the progression of other
neurodegenerative diseases such as Alzheimer’s disease. The accumulation of soluble
oligomers of the amyloid-beta peptide has been found to contribute to the neuronal
dysfunction of this disease in a PrPC-dependent way (Lauren et al., 2009). The interaction
of the amyloid-beta oligomer and PrPC leads to a variety of toxic events such as glutamate
excitotoxicity, synaptic dysfunction, and neuronal death, although the specific
mechanisms are still to be determined (Paula-Lima et al., 2013, Quenfurth et al., 2010). It
is interesting to note that both Alzheimer`s disease and prion diseases involve
aggregation of misfolded proteins. Moreover, studies have demonstrated that brains of
scrapie-infected mice showed higher beta-secretase activity compared to their control
counterparts (Parkin et al., 2007), suggesting that PrPC has an endogenous role in betasecretase modulation. As mentioned earlier, STI1 is one of the ligands of PrPC. Recent
studies have shown that STI1 can protect neurons against amyloid-beta oligomer toxicity
by binding to the PrPC and also activating the α7nAChR (Ostapchenko et al., 2013a). The
role of STI1 as a ligand for PrPC will be discussed in greater detail in the following
sections. This recent finding regarding the neuroprotective role of the prion protein and
STI1 against Alzheimer’s disease raises questions regarding what other potential
neurological insults PrPC-STI1 may protect against. Oxidative stress is often implicated
in numerous human neurodegenerative diseases such as Alzheimer’s disease and prion
disease (Beal et al., 1995, Smith et al., 2000).

1.2.3

The Role of the Prion Protein in Ischemic Conditions
In vitro studies using PC-12 rat adrenal Pheochromocytoma cells showed that the

level of prion protein expression correlated with resistance to oxidative stress, a
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component of ischemic damage (Brown et al., 1997). Furthermore, studies have shown
that during ischemic conditions, PrPC mRNA expression is increased in both human and
rodent tissues (McLennan et al., 2004). In a different study involving multicellular
prostate tumour spheroids, the authors found that the generation of reactive oxygen
species, a hallmark of ischemic damage, also led to an increase in PrPC expression (Sauer
et al., 1999). Injured neurons may increase the production of proteins vital for survival
while decreasing the synthesis of non-relevant molecules (Papadopoulos et al., 2000).
Thus, the observation that PrPC is increased in brain tissues during ischemia supports the
proposed protective role of PrPC during hypoxia. In fact, studies involving PrPC-null mice
found increased infarct volume as well as oxidative stress markers following ischemia
compared to their wild-type counterparts (McLennan et al., 2004, Wong et al., 2011,
Weise et al., 2006). In contrast, mice showing overexpression of PrPC by adenovirusmediated gene targeting demonstrated presented decreased injury and behavioural
dysfunction compared to control animals (Shyu et al., 2011, Weise et al., 2008). These
studies involving genetically modified mice with a knockout or overexpression of PrPC
suggests a potential role for PrPC during ischemia.

1.2.4

Prion Protein Ligands and Targets
The prion protein serves as a receptor for the extracellular matrix proteins laminin

and vitronectin in modulation of neuronal processes such as neuritogenesis and axonal
growth, respectively (Graner et al., 2000, Hajj et al., 2007). The binding of neural cell
adhesion molecules to PrPC has been found to be involved in the differentiation of
neuronal stem cells (Schmitt-Ulms et al., 2001, Prodromidou et al., 2014). PrPC has also
been found to play a role in the homeostasis of serotonergic neuronal cells by modulation
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of serotonergic G protein-coupled receptors (Mouillet-Richard et al., 2005). The laminin
γ1 chain has been found to contain the laminin binding site for PrPC, and laminin-PrPC
interaction leads to neuritogenesis and intracellular calcium mobilization modulated by
metabotropic glutamate receptors (Beraldo et al., 2011).
Glutamate is the major excitatory neurotransmitter in the central nervous system
(Mayer, 2005). Glutamate acts upon both ionotropic (ion channels) and metabotropic (G
protein-coupled receptors) glutamate receptors. AMPA, kainate, and NMDA receptors
belong to the ionotropic glutamate receptor family (Mayer, 2005). During depolarization,
the magnesium ion block of the channel pore is removed and activation of NMDA
receptors by co-agonists glutamate and glycine or D-serine mediates the influx of sodium
and calcium ions that results in excitatory postsynaptic potentials (EPSPs) (Mayer, 2005).
However, during excitotoxicity, excess glutamate causes aberrant NMDA activity and
subsequent uncontrolled calcium influx (Lau et al., 2010). The prion protein has been
shown to attenuate excitotoxicity in hippocampal neurons by inhibiting NMDA receptors
(Houman et al., 2008). Furthermore, up-regulation of NMDA receptors containing NR2D
subunits and the resulting prolonged NMDA-evoked current was found in PrPC-knockout
mouse hippocampal neurons, an effect that was reversed by treatment with exogenous
PrPC (Houman et al., 2008). Taken together, these results suggest that PrPC might be
important for the modulation of NMDA receptors during excitotoxicity.
Based on the multi-faceted cellular mechanisms that PrPC is involved in, this GPIanchored protein has been suggested to play the role of a scaffolding protein, serving as a
receptor for a wide range of neuronal functions (Linden et al., 2008). The major
characteristics of prion diseases are similar between mice and humans, as PrPC is a
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conserved protein between the two species. Coupled with the similarities in PrPC
expression following hypoxia, this suggests that the use of mouse models for studying the
role of PrPC is appropriate. Understanding the underlying mechanisms of PrPC and its
neuroprotective roles may help uncover novel mechanisms that could be applied to
treatment of an array of neurodegenerative diseases.

1.3 Stress-inducible phosphoprotein-1
1.3.1

STI1 structure
Stress-inducible phosphoprotein-1 (STI1), also known as the Hsp70/Hsp90

organising protein (Hop), has recently received attention in the literature for its wide
range of roles in both healthy and diseased cells. The structure of STI1 is composed of
two types of domains: the tetratricopeptide repeat (TPR) motif domain and the aspartateprotein (DP) motif domain. There are three TPR domains and two DP domains (Scheufler
et al., 2000, Brinker et al., 2002). The TPR domains, responsible for protein-protein
interactions, are involved in many cellular processes such as transcription and protein
degradation (Allan and Ratajczak, 2011).

1.3.2

Intracellular roles of STI1
In eukaryotic cells, the final stages of translation often require heat-shock protein

chaperones that assist in the folding of the final protein structure. Within the cell, heat
shock proteins are expressed abundantly in both cytoplasm and the nucleus (Lassle et al.,
1997). Without the actions of chaperones, proteins will begin to aggregate due to exposed
hydrophobic residues (Martin 2004). Hsp90, a 90kDa chaperone, is important for the
final folding steps of many regulatory client proteins (Lee et al., 2012). The binding of
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client proteins to Hsp90 requires prior interactions between Hsp70 and STI1. STI1 acts as
a co-chaperone that helps the transfer of client proteins from Hsp70 to Hsp90 by binding
onto both simultaneously via its TPR domains (Lassle et al., 1997, Schmid et al., 2012).
Studies have shown that from the three TPR domains, the TPR1 and TPR2B domains are
responsible for Hsp70 binding, while the TPR2AB domain is responsible for Hsp90
binding (Odunuga et al., 2003, Rohl et al., 2015). Formation of this protein complex
plays a role in many cellular functions in addition to protein folding, such as viral
replication, cell division, and signal transduction (Hu et al., 2002). Without the cochaperone activity of STI1, the level of client proteins of Hsp90, including kinases,
transcription factors, and steroid hormone receptors responsible for proliferation,
apoptosis, and tumorigenesis, are significantly decreased (Caplan et al., 2007, Lanneau et
al., 2008, Miyata et al., 2013, Walsh et al., 2011, Beraldo et al., 2013).
The role of STI1 also extends to cancerous cells such as breast cancer and colon
cancer cells (Willmer et al., 2013, Kubota et al., 2010). In breast cancer cells, STI1 has
been found to be expressed in isolated pseudopodia fractions and localized with actin in
lamellipodia, suggesting that STI1 may regulate cell migration (Willmer et al., 2013).
STI1 expression has also been found to be increased in colon cancer cells, and the level
of STI1 expression has been correlated with Hsp90 expression in tumour tissues (Kubota
et al., 2010). However, the exact involvement of STI1 is not fully understood. Overall,
studies have shown that inhibition of STI1 is toxic to cancer cells, as many of the client
proteins of Hsp90 are involved oncogenic activity (Horibe et al., 2011). As a result, STI1
has been recently studied as a potential therapeutic target for cancer cells (Walsh et al.,
2011, Willmer et al., 2013).
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STI1 has also been identified as a regulator of the cellular stress response in C.
elegans models (Song et al., 2009). In these models, both STI1 mRNA and protein
expression is increased following heat stress, and STI1-knockout mutants have shortened
life spans, thus suggesting that STI1 is involved in stress responses and longevity. The
authors further suggest that the two roles are related, as stress events can induce increased
expression of pro-survival genes, and in turn increasing longevity of the organism. In
fact, in C. elegans, the genes that regulate lifespan including those in the insulinsignalling pathway also regulate thermo-tolerance (Ogg et al., 1997).
As previously mentioned, deletion of the prion protein gene Pnrp is nonessential
for viability (Büeler et al., 1992). In contrast, STI1 appears to play a critical role during
embryonic development. Studies involving genetically modified mice with deletion of the
STI1 gene (Stip1) have led to the finding that mice homozygous for the STI1 knockout
died at E9.5-E10.5 (Beraldo et al., 2013). More specifically, in these mutant mice, the
client proteins of Hsp90 have been found to be significantly reduced, indicating that the
cochaperone activity of STI1 for Hsp90 is important during early development.
Interestingly, deletion of Stip1 is not lethal in C. elegans and yeast (Chang et al., 1997,
Song et al., 2009), suggesting that despite the conservation of STI1 across a variety of
species, there is evidence of evolution and further functions of STI1 in higher organisms.
STI1 has also been found to be secreted by several different types of cells (Santos
et al., 2011, Lima et al., 2007, Arantes et al., 2009, Erlich et al., 2007, Tsai et al., 2012).
Secreted STI1 appears to function as a cytokine, inducing a wide range of signalling
pathways (Hajj et al., 2013, Beraldo et al., 2010, Caetano et al., 2008, Erlich et al., 2007,
Tsai et al., 2012) (See Table 2 for a summary of the roles of STI1).
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Table 2: Cellular roles of STI1
Cell type/Model

Targets

Function

Reference

Intracellular function Hsp70/Hsp90

Cochaperone

Lassle et al., 1997

Retinal/Hippocampal PrPC
Neurons

Neuroprotection

Beraldo et al., 2010

Neuritogenesis
Hippocampal
neurons

PrPC/ α7nAChR

Protection against
soluble AβO in
Alzheimer`s disease

Ostapchenko et al.,
2013a

Ovarian Cancer
Cells

ALK2-SMAD
signalling

Cell proliferation

Tsai et al., 2012

Neurons

PrPC + PKA and
ERK1/2

Neuroprotection

Lopes et al., 2005

Neuritogenesis
Ischemic brain in
vivo

Bone Marrow
Derived Cells

Proliferation

Lee at al., 2013

Migration
Neurons

PrPC- PI3K -mTOR

Embryonic mouse
model
C. elegans

Hsp

Protein Synthesis

Roffe et al., 2010

Embryonic
development

Beraldo et al., 2013

Stress-response

Song et al., 2009

Fertility/Lifespan
Breast cancer cells

Actin

Cell migration

Willmer et al., 2013

Colon cancer

Hsp70/90

Upregulation of Hsp Kubota et al., 2010
complex formation
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1.3.3

Secretion and binding of STI1 to Prion Protein
STI1 has been found to be a ligand of PrPC and STI1-PrPC binding leads to a

plethora of signalling cascades responsible for neuronal events such as neuritogenesis,
neuronal protein synthesis, neuroprotection against staurosporine and ischemia (Zanata et
al., 2002, Chiarini et al., 2002, Lopes et al., 2005, Roffe et al., 2010, Caetano et al., 2008,
Beraldo et al., 2010, Beraldo et al., 2013). The secretion mechanism of STI1 is rather
unconventional, as STI1 lacks a signalling peptide. STI1 is secreted by astrocytes and
other cells, likely via a diverse population of extracellular vesicles derived from multivesicular bodies (Hajj et al., 2013). Extracellular vesicles released by astrocytes have
been shown to contain STI1 on the outer leaflet, and the association of STI1 with these
extracellular vesicles greatly increased STI1 activity on PrPC (Hajj et al., 2013). The
binding sites of STI1 to PrPC have been identified as amino acids 113-128 on the prion
protein, and 230-245 on STI1 (Zanata et al., 2002). The interaction between the two
proteins is specific and shows high affinity, with a Kd of 10-7 M (Zanata et al., 2002,
Ostapchenko et al., 2013).
Endocytosis of the PrPC following STI1 binding has been found to be an
important step in PrPC-STI1 signalling pathways. By using both STI1 and STI1Δ230-245
(deletion of PrPC-binding site), it was determined that STI1 treatment yielded in
dynamin-dependent PrPC-internalization, an effect that is not observed with STI1Δ230-245
(Caetano et al., 2008). Endocytosis of PrPC has been found to be a necessary step for
STI1-induced ERK1/2 activation, which in turn has been shown to promote neuronal
differentiation and synaptic plasticity (Lopes et al., 2005, Coitinho et al., 2007).
Furthermore, STI1 itself was found to be internalized in a manner independent of the

23

PrPC (Caetano et al., 2008). These results indicate that although STI1-PrPC engagement
on the cell surface results in endocytosis, the interaction between the two proteins is only
transient once internalized.
STI1 has been shown to convey neuroprotection of both retinal and hippocampal
neurons against staurosporine-induced programmed cell death by the activation of protein
kinase A (PKA) (Chiarini et al., 2002, Zanata et al., 2002, Lopes 2005, Beraldo et al.,
2010). Unlike STI1-induced ERK1/2 activation, PKA activation does not require
endocytosis of PrPC (Caetano et al., 2008). Furthermore, the interaction between STI1
and PrPC was found to induce both differentiation and protein synthesis in hippocampal
neurons through the extracellular signal-regulated kinase 1 and 2 (ERK1/2) and
phosphoinositide 3-kinase (PI3K)-Akt mTOR activation, respectively (Lopes et al., 2005,
Roffe et al., 2010). Both neuroprotection and neuritogenesis mediated by the interaction
of PrPC with STI1 in hippocampal neurons depends on the α7nACh receptor, and
inhibition of the latter with the selective α7nACh receptor antagonist α-bungarotoxin
blocks these effects (Beraldo et al., 2010).
Although many extracellular functions of STI1 depend on PrPC, few PrPCindependent roles have been identified. Recently, expression and secretion of STI1 has
been identified in both ovarian cancer cells and glioblastomas and has been shown to
induce intracellular signalling pathways that leads to cell proliferation (Tsai et al., 2012,
Erlich et al., 2007). However, the proliferative effect of extracellular STI1 on glioma has
been suspected to have both PrPC-dependent and –independent mechanisms (Erlich et al.,
2007). Taken together, it appears that the role of STI1 expands beyond just being a ligand
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for PrPC. However, these studies have not directly provided evidence that the PrPC is not
involved, thus it is still possible that PrPC also play a role in these mechanisms.

1.3.4

STI1 during Ischemia
Recently, studies have shown that STI1 protein secretion from astrocytes is

significantly increased following oxygen glucose deprivation (OGD) (Beraldo et al.,
2013). In fact, 9 hours following OGD, there is a 3-fold increase in extracellular STI1
levels (Beraldo et al., 2013). This increased STI1 expression during hypoxic conditions
has been found to result from direct binding of the hypoxia inducible factor-1-alpha onto
the promoter of STI1 gene (Lee at al., 2013).
The recruitment of bone marrow-derived endothelial cells has been described as
an endogenous recovery mechanism in the brain following stroke (Hess et al., 2002).
Recently, STI1 has also been shown to recruit bone marrow-derived stem cells (BMDCs)
into ischemic brains in vivo (Lee et al., 2013). Furthermore, STI1 signalling promoted the
proliferation and migration of BMDCs in vitro (Lee et al., 2013), suggesting that the
recruitment of BMDCs into hypoxic areas of the brain by STI1 may be an endogenous
response to facilitate recovery following ischemia.
Apoptosis and necrosis are two forms of cell death with distinct morphological
features. While necrosis is a passive, irreversible process, apoptosis is much more active
and requires the action of numerous apoptotic regulatory proteins (Walker et al., 1988).
There are two types of apoptosis. The first type is intrinsic and involves the mitochondria.
The second type depends on the action of membrane death receptors, and is thus extrinsic
(Walker et al., 1988). In intrinsic apoptosis, the balance of both pro-apoptotic proteins
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(such as BIM and Bax) and anti-apoptotic proteins (such as Bcl-2 and BclXL) regulate the
release of cytochrome c from the mitochondria. In both forms of apoptosis, caspase
enzymes are activated and damages occur to the DNA, chromatin, and the plasma
membrane (Walker et al., 1988). Cyclic AMP (cAMP) is one of the most well studied
second messengers, especially in regulation of apoptosis. In neuronal cell types, cAMP
has been found to have an anti-apoptotic effect (Insel et al., 2012). Activation of PKA, an
effector of cAMP, has been found to protect cells against TNF-alpha-induced apoptosis
(Kragsted et al., 2004).
Anisomycin induces apoptosis by inhibition of protein synthesis (Croons et al.,
2009). In early studies, activation of PrPC using a PrPC-binding peptide modeling STI1
was found to transduce neuroprotective signals against anisomycin-induced apoptosis in
retinal cells (Chiarini et al., 2002). While activation of PrPC has been found to activate
both cAMP/PKA and ERK pathways, inhibition of PKA activity blocked the protective
effect of PrPC (Chiarini et al., 2002). Treatment of hippocampal neurons with STI1 led to
a PrPC-dependent increase of PKA activity to a level similar to that observed with
forskolin, a potent activator of PKA (Lopes et al., 2005). Furthermore, PrPC has been
documented to modulate calcium signalling (Whatley et la., 1995). In fact, the interaction
between STI1 and PrPC triggers calcium influx via physical interaction with the
α7nAChR, leading to protection against staurosporine-induced apoptosis (Beraldo et al.,
2010). Unlike the massive influx of calcium during excitotoxicity, this controlled
increment of calcium influx via α7nAChR is upstream of PKA activation and is
subsequently protective against staurosporine (Cooper et al., 1995, Beraldo et al., 2010).
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1.4 Alpha-7 nicotinic acetylcholine receptor
In intra-cerebral haemorrhage, the development of brain edema induces apoptosis
in surrounding neurons, extending the damage beyond the initial site of ischemia
(Matsushika et al., 2000). Secondary injury mechanisms, such as the inflammatory
cascade, are significant contributors to neuronal ischemic damage (Keep et al., 2012,
Lakhan et al., 2009). Excessive inflammation and the production of tumour necrosis
factor (TNF) leads to tissue injury and cell death (Tracey et al., 1986). The α7nAChR is a
member of the nicotinic acetylcholine receptor family and has been shown to have an
important role in anti-inflammatory pathways (Rosas-Ballina et al., 2009). These
receptors are ligand-gated pentameric ion channels that transmit signals for acetylcholine
at neuromuscular junctions in both the central and peripheral nervous systems (Leonard
and Bertrand, 2001, Marubio and Changeux, 2000). In human macrophages,
acetylcholine has been found to target nicotinic receptors and inhibit the release of
inflammatory cytokines such as TNF (Borovikova et al., 2000). Acetylcholine agonists
such as nicotine have anti-inflammatory effects by inhibition of cytokine synthesis in
numerous cell types (Sadis et al., 2007). However, the role of the α7nAChR during
ischemia in the central nervous system is not completely understood.
In rats, stimulation of the α7nAChR has been shown to attenuate apoptosis
induced by subarachnoid haemorrhage by down-regulation of caspase-3 activity via
increased Ak2 phosphorylation (Duris et al., 2011). More specifically, in neurons,
activation of Akt leads to inhibition of glycogen synthase kinase-3β (GSK-3β) (Grimes
and Jope, 2001), an enzyme that shows increased expression following oxygen-glucose
deprivation in ischemic stroke (Valerio et al., 2011). During ischemia, phosphorylation of
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GSK-3β in specific residues involved in its activity is increased, and the activated GSK3β induces caspase-3 activation and subsequent apoptosis (King et al., 2001). In addition,
inhibition of GSK-3β also increases the expression of β-catenin, an important component
of the blood brain barrier (Nelson and Nusse, 2004). Hence, increased phosphorylation of
Akt by α7nAChR activation leads to decreased GSK-3β activity, thereby attenuating
apoptosis and blood brain barrier degradation following ischemia.
Furthermore, studies using murine models of intra-cerebral haemorrhage have
shown that activation of the α7nAChR via PHA-543613 (an agonist of the α7nAChR)
leads to attenuation of behavioural deficits such as sensorimotor function, reflexive motor
ability, and spatial exploratory and cognitive performance (Krafft et al., 2012). In
contrast, treatment with MLA (a selective α7nAChR antagonist) leads to exacerbation of
these behavioural deficits (Krafft et al., 2012). The authors suggested that the activation
of the α7nAChR lead to both anti-apoptotic and anti-inflammatory effects via the
inhibition of pro-inflammatory cytokines. More recently, studies have shown that PNU
282,987, a selective α7nAChR agonist, protects against hepatic ischemia-reperfusion
injury (Li et al., 2013). It was found that treatment with PNU 282,987 attenuated liver
injury following ischemia-reperfusion by suppression of cytokine and NF-κB activation.
These findings further suggest that activation of the α7nAChR leads to attenuation of
apoptosis and inflammation.
Interestingly, a recent study found that hippocampal cultures treated with
melatonin during reperfusion protected against OGD (Parada et al., 2014). The protective
effect of melatonin was prevented when co-treated with α-bungarotoxin, a selective
α7nAChR antagonist, indicating that the α7nAChR plays a critical role in the protective
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effect of melatonin against OGD (Parada et al., 2014). The authors suggest that the
activation of the α7nAChR and subsequent overexpression of heme oxygenase-1, a key
enzyme in the protection against oxidative and inflammatory stress (Kim et al., 2005),
greatly contributes to the neuroprotective effect of melatonin (Parada et al., 2014). In vivo
studies demonstrate that melatonin administration following stroke results in reduced
infarct size and attenuated behaviour deficits, while administration of MLA partially
blocks the protective effect of melatonin (Parada et al., 2014).
Recently the α7nAChR has been identified in signalling pathways of STI1 and
PrPC in hippocampal neurons (Beraldo et al., 2010, Ostapchenko et al., 2013a). STI1
binding to PrPC leads to a physical interaction with the α7nAChR, inducing calcium
influx required for protection against staurosporine-induced apoptosis via PKA activity
(Beraldo et al., 2010). Since calcium influx induced by STI1 is abolished in both PrPCnull neurons or with α7nAChR inhibition, STI1-PrPC interaction is suggested to be
upstream of α7nAChR-induced calcium influx (Beraldo et al., 2010). One possible
mechanism could be that STI1-PrPC modulates the responsiveness of the α7nAChR to
choline present in the extracellular milieu, since the concentration of choline is too low to
activate the α7nAChR under basal conditions (Beraldo et al., 2010). The signalling
pathways activated by STI1 and α7nAChR overlap, including ERK1/2 inducing
neuritogenesis and PKA inducing neuroprotection (Caetano et al., 2008, Beraldo et al.,
2010). However, the role of the α7nAChR in OGD-induced apoptosis is not fully
understood.
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1.5 ALK2 receptor
1.5.1

Activin receptors
ALK2 receptors are members of the activin receptor family, a group of growth

and differentiation factors that belong to the transforming growth factor-beta (TGF-β)
superfamily (Shi et al., 2003). These receptors are involved in various cell functions
including cell proliferation and migration (Kitisin et al., 2007). Activin receptors are
involved in many biological processes during early development, particularly in the
differentiation of stem cells during organogenesis (Pauklin et al., 2015). In embryonic
stem cells, activin signalling has been documented to be both necessary and sufficient in
the maintenance of pluripotency of the epiblast (Vallier et al., 2004). On the other hand,
activin signalling has been found to be an important step for the differentiation of adult
stem cells (Kadaja et al., 2014). In the brain, activin signalling has been found to induce
the differentiation of neural stem cells into cortical interneurons (Cambray et la., 2012).
However, reliable detection of activin receptors has been difficult, and their roles in adult
tissues are yet to be fully understood (Pauklin et al., 2015). Interestingly, it has recently
been shown that decreased activity of the Activin A-Smad pathway leads to increased
sensitivity to OGD as evidenced by higher apoptosis rates, suggesting that this pathway
plays a neuroprotective role against OGD (Wang et al., 2013).

1.5.2

Activin signalling
Activin receptors have a cysteine-rich extracellular domain, a trans-membrane

domain, and a cytoplasmic serine/threonine-rich domain (Kitisin et al., 2007). There are
two types of activin receptors, categorized as type-I or type-II. Seven type-I receptors and
five type-II receptors have been identified in the human genome (Manning et al., 2002).
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All activin receptors transduce signals in a similar manner that involves one of each
receptor dimers (Shi et al., 2003). Activation of type II receptor dimers (which are
typically responsible for ligand-binding specificity) via ligand binding recruits the
corresponding type I receptor dimer to form a hetero-tetrameric complex (Hardwick et
al., 2008). Type II receptors, which are serine/threonine kinase receptors, phosphorylate
serine residues on type I receptors (Kitisin et al., 2007). Generally, type-I receptors
determine the downstream signalling pathway to be activated (Shi et al., 2003). Once
type I receptors are phosphorylated, SMAD anchor for receptor activation (SARA)
recruits receptor-regulated SMADs (R-SMADs) and orients the serine residue on the Cterminus of the R-SMAD for phosphorylation by the type I receptor (Kitisin et al., 2007).
The phosphorylated R-SMADs dissociate from SARA, bind onto a co-SMADs, and form
a complex that migrate to the nucleus and binds transcription factors to induce changes in
gene expression (Kitisin et al., 2007).

1.5.3

BMP-4 in the brain
Bone morphogenetic proteins (BMPs) were first identified in protein extracts that

were able to induce cartilage formation and de novo bone growth (Wozney et al., 1988).
Since then, more than 20 BMPs have been identified and comprise the largest subgroup
of the TGF-beta superfamily, with a wide range of cellular roles in addition to
differentiation including proliferation, morphogenesis, and apoptosis (Hogan, 1996).
Despite their wide range of cellular mechanisms, all BMPs signal in a similar fashion
compared to other TGF-beta superfamily members, which is through activin receptors
(Shi et al., 2003). BMP-4 has been found to play a critical role in the differentiation of
neural stem cells (NSCs) into neurons, oligodendrocytes, and astrocytes during periods of
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spatiotemporal development (Abematsu et al., 2006). Recent studies have shown that
BMP-2 and BMP4 are highly expressed in astrocytes, thus identifying astrocytes as a
major source of BMPs during development and differentiation of NSCs (Hu et al., 2012).
Outside of the central nervous system, BMP signalling has also been identified in
the mammalian neuromuscular system (Chou et al., 2013). In neuromuscular junctions,
BMP-4 has been identified to be expressed by Schwann cells and skeletal muscle fibers
(Chou et al., 2013). During embryonic development, peripherally derived BMP-4 was
found to play a role in the survival of motor neurons by protecting the cells from
glutamate toxicity (Chou et al., 2013). However, whether or not BMP-4 can protect CNS
neurons from other types of toxicity during ischemia is not well understood.

1.5.4

STI1 signalling via ALK2
Recent work has shown that ovarian cancer cells release large amounts of STI1

into the blood (Tsai et al. 2013). As a result, STI1 concentrations in the blood stream can
be used as a potential diagnostic biomarker for patients with suspected ovarian cancer
(Wang et al., 2010, Kim et al., 2010). Additionally it has been shown that in cancer cells,
STI1 acts as a cytokine to stimulate cell proliferation (Wang et al., 2010). More recently,
it has been shown that ALK2 receptors (Activin A receptor, type 1 or ACVR1) can be
directly activated by STI1 in ovarian cancer cells (Tsai et al., 2012). Secreted STI1,
acting in an autocrine and paracrine fashion, binds and activates ALK2, which results in
cell proliferation via SMAD-regulated transcription of target genes such as inhibitor of
DNA binding (IDs) and increased protein synthesis (Tsai et al., 2012). However, whether
this STI1 signalling pathway is present in neurons is unknown.
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1.5.5

The role of activin receptors during ischemia
A recent study focused on the role of SARA during ischemia showed that

expression of SARA was significantly increased following OGD in PC12 cells (Wang et
al., 2013). Furthermore, down-regulation of SARA by siRNA lead to decreased mRNA
expression of Smad2, 3, and 4, as well as decreased phosphorylation of the Smad2
protein (Wang et al., 2013). As a result of decreased SARA activity and ultimately the
Activin A-Smads pathway, there was an increased sensitivity in PC12 cells to OGD as
evidenced by higher apoptosis rates. Taken together, the authors suggested that SARA,
along with the ActA/Smad pathway, may play a protective role against OGD (Wang et
al., 2013).
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1.6 Rationale, Study Aim, and Hypothesis
Current treatment for ischemic stroke is limited to intra-venous thrombolytic
therapy. Recent studies have shown that the therapeutic window of thrombolytic therapy
is within 4 hours following ischemic onset (Lansberg et al., 2012). To develop novel
therapies for stroke, the molecular mechanisms by which the brain protects itself against
ischemia must be fully understood. One of these mechanisms activated during ischemia
involves PrPC and STI1. Studies have shown that the expression of both PrPC and STI1
are increased during stroke, and that the level of PrPC expression directly correlates with
resistance against oxidative stress (McLennan et al., 2004, Lee et al., 2013, Brown et al.,
1997). STI1, the ligand for PrPC, has recently been shown to protect neurons from OGDinduced cell death (Beraldo et al., 2013). However, the exact mechanisms by which
STI1-PrPC protects neurons against ischemia is not fully understood. The aim of this
thesis is to investigate the role of the alpha-7 nicotinic acetylcholine receptor and the
ALK2 receptor in STI1-PrPC-mediated protection against ischemia.
One of the receptors modulated by STI1-PrPC is the α7nAChR. The binding of
STI1 to PrPC leads to calcium influx via the α7nAChR (Beraldo et al., 2010).
Furthermore, the protective effect of STI1 against staurosporine has been previously
shown to depend on the α7nAChR (Beraldo et al., 2010). On the other hand, STI1 has
also been shown to induce cell proliferation in ovarian cancer cells via the ALK2 receptor
of the activin receptor family (Tsai et al., 2012). Recent studies have shown that
inhibition of the downstream effectors of activin receptors exacerbates damage induced
by OGD (Wang et al., 2013). However, the involvement of the α7nAChR and the ALK2
receptor in STI1-PrPC-mediated neuroprotection against ischemia is unknown. We
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hypothesize that the α7nAChR is required for STI1-PrPC-mediated neuroprotection
against OGD.
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2

Materials and Methods

2.1 Animals
The caspase 3 reporter mouse line (ApoMouse, Nicholls et al., submitted)
provides a way to identify living neurons that will undergo caspase-3-mediated apoptosis
in response to insults. This mouse line is genetically modified to express cerulean
fluorescent protein (CFP). Activated caspase can be identified thanks to using
bimolecular complementation technique (ApoMouse, Nicholls et al., submitted). The
prion protein-knockout mouse line (Prnp0/0), descendants of the Zrchl line, originally
generated by Dr. Charles Weissman (Scripps Florida) was provided by Dr. Frank Jirik
(University of Calgary), and had been backcrossed to C57BL/j for 10 generations
(Khosrayani et al., 2008). The α7nAChR-knockout mouse line (B6.129S7-Chrna7tm1Bay/J)
was purchased from Jax labs. The mouse line was originated on a mixed C57BL/6 and
129/SveV background and posteriorly backcrossed to C56BL/6 for more than 8
generations. The mouse was developed by the deletion of the last three exons of the
Chrna7 gene. Table 3 provides a summary of mice used in this thesis.

2.2 Ethics Statement
The animals used in this research were maintained by the University of Western
Ontario Animal Care and Veterinarian Services. All procedures were done in accordance
with approved animal use protocols at the University of Western Ontario (2008-127)
(Appendix 1) following the guidelines of the Canadian Council of Animal Care (CCAC).
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Table 3: Mouse lines used in this thesis
Strain

Background

Origin

Modification

Prnp0/0
(Zurich)

C57BL/6j

C. Weissmann
but strain
donated by Frank
Jirik (U.
Calgary)

Prnp (PrPC)
knockout

B6.129S7
Chrna7tm1
Bay/J

C57BL/6

Jax labs

Apo mice

C57BL/6

Generated by
Marc Caron at
Duke University
Medical Centre

Use

To determine if
neuroprotection by
STI1 against OGD
in vitro is dependent
on the PrPC
Chrna7 (alpha7
To determine the
nicotinic receptor) role of α7nAChR in
the STI1-PrPC –
mediated
neuroprotection in
vitro against OGD
Bimolecular
fluorescence
complementation
technique of the
Cerulean protein

To determine the
caspase-3 activity of
neurons following
OGD
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2.3 Reagents
Mouse recombinant STI1 (His6-STI1) was generated and purified as described
previously (Zanata et al., 2002). Staurosporine (Invitrogen Burlington ON, Canada), a
protein kinase inhibitor that triggers apoptosis, was used as a positive control in apoptosis
experiments (Chae et al., 2000). Staurosporine was dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 25mg/mL and stored at -20°C. The concentrations used for
staurosporine were chosen based on their effectiveness at inducing apoptosis in neuronal
cultures as determined by our previous studies (Beraldo et al., 2010). The competitive
inhibitor of α7nAChR, methyllyeaconitine citrate (MLA, Abcam Cambridge MA, USA),
was used to determine if the α7nAChR is involved in the effects of STI1 (Bertrand et al.,
1997). MLA was dissolved in saline at a concentration of 100mM and stored at -20°C. To
activate α7nAChR, its agonist PNU282987 [(N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4chlorobenzamide hydrochloride) Abcam Cambridge MA, USA] was used (Hajós et al.,
2005). PNU 282987 was dissolved in water at a concentration of 100mM and stored at 20°C. Effective final concentrations used for MLA and PNU 282987 in neuronal cultures
were determined by previous studies at 20nM and 0.5μM, respectively (Bodnar et al.,
2005, Hu et al., 2007, Cheng et al., 2014). To inhibit the ALK2 receptor, LDN193189
(Abcam Cambridge MA, USA), a small molecule inhibitor of bone morphogenetic
protein type 1 receptors, was used (Cuny et al., 2008). LDN 193189 was dissolved in
water at a concentration of 10mM and stored at -20°C. Final LDN 193189 concentrations
used were determined by previous experiments describing its effect as a highly selective
antagonist of ALK2 at 5nM (Yu et al., 2008). BMP-4 (Sigma-Aldrich St. Louis MO,
USA), a polypeptide from the TGF-beta superfamily of proteins, was used as an agonist
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to ALK2 receptors (Chaikuad et al., 2012). BMP-4 was dissolved in 10mM citric acid at
a concentration of 1mg/mL and stored at -20°C. BMP-4 (EC50 ranging from 5 – 10
ng/mL) used in our LIVE/DEAD experiments (final concentration of10ng/mL 100ng/mL) was determined by previous experiments that found 100ng/mL to be effective
in vitro (Vrijens et al., 2013, La Rosa et al., 2011).

2.4 Primary cell culture
Male and female mice were paired and kept in the same cage for 3 days. After 3
days, mice were separated into individual cages. This provided a 3-day window of
estimation for the age of the embryos. On day 15, successful mating was determined by
observing the abdomen of the female mouse for visual confirmation of pregnancy.
Pregnant females were euthanized by decapitation at embryonic day 17 and embryos
were collected and kept on glass plates over ice until dissection. Embryonic brains were
dissected under the microscope for removal of the cortex and the hippocampus. In brief,
the mouse brain was separated into halves along the sagittal section (Figure 1A,B). With
the superficial surface facing down, the meninges were removed from the forebrain by
gently grasping the olfactory bulb using forceps (Figure 1C,D). Then, the midbrain was
separated from the forebrain. Once again with the superficial surface of the forebrain
facing down, the hippocampus was observed and removed from the cortex using forceps
(Figure 1E,F). Once separated, the fimbriae of the hippocampus were removed by careful
clipping using forceps (Figure 1H). Tissues were kept on ice in Eppendorf tubes with
Hank’s Balance Salt Solution (HBSS) until tissue dissociation.
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Figure 1: Dissection of hippocampus and cortex from embryonic E16.5 brains. (a)
The E16.5 mouse brain is (b) cut into halves via the midline sagittal section. (c) The
halves are placed such that the cortex is facing up. (d) Meninges (arrows) are removed
from the hemispheres with Dumont no. 5 forceps by gently pulling. (e) While holding the
brainstem, the cortex (cx) is flipped outward and clipped off the midbrain. (f) The
hippocampus (hip) is visible on the inner surface of the forebrain. (g) The hippocampus is
removed with a microscissor. (h) Cortex (cx) and hippocampus (hip) are separated. (i,j)
The fimbriae (arrowhead) on the concave side of the hippocampus are removed (open
arrowhead). Image from Fath et al., 2008.
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HBSS was then replaced with 37 °C trypsin-EDTA (0.25%, phenol red, (Life
Technologies Burlington ON, Canada) and tubes were placed for 20 minutes in a 37°C
water bath for tissue dissociation. Cells were then washed with sterile plating media
(Minimum essential media with GlutaMAX, 20% Fetal Bovine Serum, 1% penicillin &
streptomycin, 1% sodium pyruvate, 1.75% glucose, (Life Technologies) and incubated
for 1 minute in plating media supplied with 0.2mg/mL DNase (Roche). Cells were then
mechanically dissociated and homogenized by careful pipetting up and down. Cell
concentration was determined by counting dissociated cells with a hemocytometer.
Number of cells plated varied according to each experiment and plate sizes. Apo mouse
neurons were plated in P35 (5 x 104 cells) glass-bottom dishes. Neurons for the
LIVE/DEAD assay were plated in 4-well P15 (8 x 104 cells) dishes. Neurons for
immunofluorescence were plated in 24-well P15 (5 x 104 cells) dishes.
Neurons were plated in dishes previously coated with poly-L-lysine under UV
light overnight and washed with sterile HBSS prior to plating (Sigma Aldrich Canada).
After 4 hours, the plating medium was removed and replaced with the maintenance
medium (Neurobasal medium supplied with 1% penicillin/streptomycin mix, 0.5mM Lglutamate, and B27 supplement, Life Technologies). Cells were maintained at 37°C and
5% carbon dioxide for 7 days before experimentation. Half of the medium was replaced
with fresh maintenance medium every two days. See Figure 2 for general experimental
timelines.
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Figure 2: Schematic illustrating the mating, culturing, and experiment of
hippocampal neurons.
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2.5 Oxygen Glucose Deprivation
For oxygen glucose deprivation (OGD) experiments, the original media of the
cells was replaced with a glucose-free maintenance media as described previously
(Beraldo et al., 2013). Cells were then placed in an incubator (AutoFlow NU-4950
Oxygen and Humidity Control Water Jacket CO2 Incubator, NuAire, Plymouth MN,
USA) with 0% oxygen (95% nitrogen/5% carbon dioxide) for 1 hour, beginning when
oxygen was completely depleted from the chamber. Upon completion of OGD, cells were
removed from the incubator, glucose-free maintenance medium was replaced with the
original maintenance medium, and the cells were returned to normal conditions at 37°C
and 5% carbon dioxide for 3, 12, or 24 hours for reperfusion (Beraldo et al., 2013).

2.6 Immunofluorescence
After 7 days of culture in vitro, hippocampal neurons were isolated from E17
wild-type mice were fixed using 2% paraformaldehyde (Millipore) and permeabilized
using 0.5% Tritton X-100 (Millipore). Cells were then blocked using 2% BSA (Sigma)
before applying the primary antibodies against NeuN (mouse, 1:200 dilution, Abcam)
and ALK2 (rabbit, 1:200 dilution, Abcam) overnight at 4°C, followed by secondary
antibodies anti-mouse Alexa Fluor-488 (1:1000 dilution, Invitrogen) and anti-rabbit
Alexa Fluor-633 (1:1000 dilution, Life Technologies) for 1 hour at room temperature.
Cells were also stained using Hoechst reagent (1μg/mL) to visualize the nucleus. Fifteen
images were taken per embryo per treatment using a LSM 510 META confocal
microscope (Zeiss Jena, Germany) equipped with 63x/1.4NA objective and analyzed
using LSM 5 software (Zeiss Jena, Germany) and ImageJ (NIH).
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2.7 Caspase-3 reporter mouse
We used a caspase 3 reporter mouse line to identify living neurons that are
undergoing caspase-3-mediated apoptosis. In a healthy cell, expression of Apo transgenes
produces two halves of CFP, tagged with recombinant sequences (inteins) and signal
peptides attached to the protein via caspase 3 cleavage site. These signal peptides contain
PEST protein degradation sequences and target CFP halves to different cellular
compartments, which prevents formation of full fluorescent CFP. In apoptotic cells,
caspasde-3 activation removes the signal peptides and the degradation sequences,
allowing the two halves to bind using complementary inteins and reconstitute the fully
functional monomeric CFP (Figure 3). Fluorescence was quantified by using a confocal
microscope (LSM 510 META, 10x, 485nm excitation, 530nm emission) and fluorescence
per cell was normalized to the control cells that were not subjected to OGD. Eight images
were taken per treatment per embryo dish, and four embryos were cultured per
experiment.
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Figure 3: Schematic illustrating the caspase-3 reporter (Apo) mouse line. (A)
Complementary inteins, subcellular localization sequences, and the PEST protein
degradation sequences were added and the two halves were separated under basal
conditions. (B) Caspase-3 activation led to cleavage of the subcellular localization and
PEST protein degradation sequence. (C) Two halves freely diffuse throughout the cell
and bind through complementary inteins. (D) Reconstitution resulted in the fully
functional and fluorescent Cerulean protein.

45

2.8 LIVE/DEAD assay
The LIVE/DEAD mammalian cell viability assay (Invitrogen, Burlington ON,
Canada) was used to analyze cell viability following OGD or staurosporine-treatment.
Calcein-AM, a membrane permeable dye that expresses green fluorescence when cleaved
by ubiquitous intracellular esterases, was used to determine the amount of live cells.
Ethidium homodimer-1, a membrane impermeable dye that expresses red fluorescence
upon binding to DNA and indicates loss of plasma membrane integrity, was used to
determine the amount of dead cells. For the Ethidium homodimer-1 dye, 15μL of the
2mM stock solution [dissolved in DMSO/H2O 1:4 (v/v)] was added per 10mL of
maintenance solution for a working concentration of 3μM. For the Calcein-AM, 2.5μL of
the 4mM stock solution (dissolved in anhydrous DMSO) was added per 10mL of
maintenance solution for a working concentration of 1μM. Following the experiment,
cells were incubated with the dye in the original maintenance medium for 30 minutes at
37°C at 5% carbon dioxide and then washed three times with Krebs-Ringers Henseleit
(KRH) solution (in mM: 125 NaCl, 5 KCl, 5 HEPES, 2.6 MgSO4, and 10 glucose, pH
7.2). After washing, the cells were imaged using an LSM 510 META confocal
microscope equipped with 10x/0.4NA objective. Calcein-AM was excited using a
fluorescein optical filter (485nm) and the Ethidium homodimer-1 was excited with a
rhodamine optical filter (530nm). Fluorescent emissions were captured at 530nm and
645nm for the Calcein-AM and the Ethidium homodimer-1, respectively. Six random
images were taken per embryo (dish) per treatment. Live (green) and dead (red) cells
were counted using the Image-based Tool for Counting Nuclei (ITCN, Center for Bioimage Informatics at UC Santa Barbara) with a diameter of 16 pixels for live cells and 8
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for dead cells. Threshold to distinguish two adjacent cells as individual cells was set at 1
pixel. Images were analyzed using ImageJ software (NIH) and cell death was calculated
as the ratio of dead cells to the total number of cells.

2.9 Statistical Analysis
Data was obtained in each condition from cultures with at least 4 independent
embryos of either sex. Caspase-3 activity from Apo mice was quantified in arbitrary units
as fluorescence per cell normalized to the control. Cell death from the live/dead
mammalian viability assay was quantified as percentage of total cells that are dead. All
data were expressed as mean +/- standard error and analyzed using one-way or two-way
ANOVA (When comparing multiple mouse lines) and Tukey’s post-hoc test performed
on GraphPad Prism (Version 5.0 for Windows, La Jolla California USA). In all cases,
P<0.05 was considered statistically significant.
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3

Results

3.1 STI1 decreases apoptosis and neuronal death induced
by OGD
To investigate the mechanisms involved with the actions of STI1 against OGDinduced cell death, hippocampal neurons obtained from a reporter mouse for caspase-3
activation were subjected to 1 hour OGD treatment and then reperfusion in the presence
or absence of STI1. Caspase-3 activity and cell death were measured in the same fields
using fluorescence from CFP and Ethidium homodimer-1 dye, respectively. Cells were
imaged at 3, 12, and 24 hours of reperfusion after OGD. As a positive control, neurons
were treated with 200nM of staurosporine for the same period of time as OGD treatment.
Increased CFP fluorescence was observed in neurons after exposure to 1 hour OGD or in
neurons treated with staurosporine as early as 3 hours after treatment (Figure 4A,B;
P<0.05). Interestingly, the time course of apoptosis fluorescence is distinct from the cell
death fluorescence. Cerulean fluorescence was higher at 3 hours of reperfusion and
decreased with time, whereas labeling of dead cells increased progressively until 24
hours (Figure 4A,B). Treatment of neurons with STI1 significantly decreased caspaseinduced fluorescence compared to non-treated cells (Figure 4A,B; P<0.05). Furthermore,
cell death in neurons treated with STI1 was also significantly lower than non-treated
neurons in all 3 durations of reperfusion (Figure 4A,C; P<0.05).
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Figure 4: Time course of caspase-3 activity and cell death in neurons treated with
STI1 and OGD. Apo mouse hippocampal neurons were treated with 1μM of
recombinant STI1 (1μM, 30 minutes) and then subjected to 1 hour OGD. Cells were
imaged at 3, 12, and 24 hours of reperfusion. (A) Representative images of cells per
treatment at different time points as indicated on the left. Green fluorescence indicates
activated caspase-3 and red fluorescence (Ethidium Homodimer-1 staining) indicates
dead cells. Neurons treated with staurosporine for 3, 12, and 24 hours were also imaged
using the same methods. (B,C) Caspase-3 activity was quantified in arbitrary units as
fluorescence per cell normalized to the control. Cell death was quantified as percentage
of total cells that were dead. Treatment of neurons with STI1 significantly decreased
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caspase-3 fluorescence in all 3 durations of reperfusion. The number of dead cells in
neurons treated with STI1 remained significantly lower than on neurons that were not
treated with STI1 (OGD)- or staurosporine-treated cells. *P<0.05. Results are presented
as mean +/- SEM; data were analyzed and compared by two-way ANOVA and Tukey’s
post hoc test. (n=4).
Previous experiments have suggested that STI1-mediated neuroprotection against
staurosporine or OGD-induced cell death is PrPC-dependent (Lopes et al., 2005, Caetano
et al., 2008, Beraldo et al., 2010, Beraldo et al., 2013). To confirm whether STI1 prevents
neuronal death in a PrPC-dependent way, wild-type and Prnp0/0 hippocampal neurons
were treated with STI1 (1μM) and then submitted to 1 hour OGD and 24 hour reperfusion
prior to live/dead imaging. Treatment with STI1 significantly decreased cell death
induced by OGD in wild-type neurons (Figure 5; P<0.05). However, treatment with STI1
was ineffective to decrease cell death in Prnp0/0 hippocampal neurons (Figure 5).
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Figure 5: Treatment of wild-type and Prnp0/0 hippocampal neurons with STI1 and
OGD. Wild-type (n=4) and Pnrp0/0 (n=4) hippocampal neurons were treated with
recombinant STI1 (1μM, 30 minutes) and then subjected to 1 hour OGD. (A)
Representative images obtained by confocal microscopy. (B) Cell death was quantified as
percentage of total cells that were dead using Calcein-AM (Live, green) and Ethidium
homodimer-1 (dead, red) dyes. Treatment of neurons with STI1 decreased OGD-induced
cell death in wild-type cells, but not in Pnrp0/0 cells. Results are presented as mean +/SEM; data were analyzed and compared by two-way ANOVA and Tukey’s post hoc test.
(n=4). *P<0.05.
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3.2 STI1 engages α7nAChR for neuroprotection
Previous experiments suggested that STI1 can engage a complex containing PrPC and
α7nAChRs in hippocampal neurons for neuronal signalling and protection against
staurosporine-induced neuronal cell death (Beraldo et al., 2010). However, in other
neuronal types and cancer cells, STI1 can activate signalling independent of PrP C,
α7nAChR or both (Arruda-Carvalho et al., 2007, Tsai et al., 2012, Santos et al., 2013).
To determine whether α7nAChRs are important for STI1-mediated neuroprotection
against ischemic insults, wild-type hippocampal neurons were treated with several
concentrations of the α7nAChR-selective antagonist MLA for 30 minutes prior to
treatments with 1 μM recombinant STI1 and 1 hour OGD plus reperfusion. Inhibition of
α7nAChRs by MLA attenuated the neuroprotective effect of STI1 against OGD (Figure
6; P<0.05). Interestingly, even neurons treated with the highest dose of MLA and STI1
presented better survival than untreated neurons, where treatment with MLA was not able
to completely abrogate the neuroprotective effect of STI1 against OGD (Figure 6A,B).
To further investigate the role of α7nAChR in STI1-mediated neuroprotection against
ischemic insults, we then used cultured hippocampal neurons obtained from α7nAChRknockout mice. Hippocampal neurons were treated with 1μM of recombinant STI1 and
exposed to OGD for 1 hour and reperfused for 24 hours. Treatment of wild-type neurons
with STI1 significantly decreased cell death compared to neurons that were not treated
with STI1 (Figure 7; P<0.05), whereas this effect is lost in α7nAChR-knockout mouse
hippocampal neurons (Figure 7). In contrast, treatment of neurons with staurosporine
induced levels of cell death not significantly different between wild-type and α7nAChRknockout mouse neurons (Figure 7). These results further support the finding that STI1
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selectively engages PrPC/α7nAChRs to protect neurons against OGD/reperfusionmediated cell death.
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Figure 6: Neuroprotection by STI1 against OGD is attenuated in wild-type
hippocampal neurons treated with α7nAChR inhibitor MLA. Wild-type hippocampal
neurons were treated with a MLA (2-1000nm) and recombinant STI1 (1μM, 30 minutes)
and then subjected to 1 hour OGD. (A) Representative images obtained by confocal
microscopy after 24 hours of reperfusion. (B) Cell death was quantified as percentage of
total cells that were dead using Calcein-AM (Live, green) and Ethidium homodimer-1
(dead, red) dyes. While treatment of neurons with STI1 decreased OGD-induced cell
death, neurons were no longer protected when treated with the α7nAChR inhibitor MLA.
Results are presented as mean +/- SEM; data were analyzed and compared by one-way
ANOVA and Tukey’s post hoc test. (n=4). *P<0.05.
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Figure 7: Neuroprotection against OGD by STI1 is prevented in hippocampal
neurons from alpha-7 nicotinic acetylcholine receptor (α7nAChR) knock-out mice.
Wild-type and α7nAChR-KO hippocampal neurons were treated with recombinant STI1
(1μM, 30 minutes) and then subjected to 1 hour OGD. (A) Representative images
obtained by confocal microscopy after 24 hours of reperfusion. (B) Cell death was
quantified as percentage of total cells that were dead using Calcein-AM (live, green) and
Ethidium homodimer-1 (dead, red) dyes. Treatment of wild-type neurons with STI1
significantly decreased OGD-induced cell death, an effect not observed in α7nAChR-KO
neurons. Results are presented as mean +/- SEM; data were analyzed and compared by
two-way ANOVA and Tukey’s post hoc test. (n=4). *P < 0.05.
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3.3 Activation of the α7nAChR protects neurons against
OGD
Previous experiments have suggested that nicotinic receptors may provide a new pathway
to interfere with outcomes in hemorrhagic stroke (Krafft et al., 2012) and activation of
nicotinic receptors can protect neurons against OGD (Li et al., 2013). To further
investigate the potential for activation of α7nAChR to protect neurons against OGDinduced cell death, we used PNU 282,987, a selective α7nAChR agonist. Wild-type
mouse hippocampal neurons were treated with variable concentrations of PNU 282,987
for 30 minutes prior to exposure to OGD. Activation of α7nAChR with PNU 282,987
impaired neuronal death induced by OGD in a dose-dependent manner (Figure 8A,B;
P<0.05). Furthermore, we tested whether this effect of PNU 282,987 was selective to
α7nAChRs. Similar to the effects of STI1, PNU 282,987 was unable to prevent OGDinduced neuronal death of α7nAChR-knockout neurons (Figure 8A,C).
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Figure 8: Treatment of wild-type hippocampal neurons with the α7nAChR agonist
PNU 282,987 significantly reduced cell death due to OGD. Wild-type and α7nAChRKO hippocampal neurons were treated with recombinant STI1 (1μM) and/or PNU
282,987 (1-20 μM, 30 minutes) and then subjected to 1 hour OGD. (A) Representative
images obtained by confocal microscopy after 24 hours of reperfusion. (B,C) Cell death
was quantified as percentage of total cells that were dead using Calcein-AM (live, green)
and Ethidium homodimer-1 (dead, red) dyes. Treatment of neurons with 20μM of PNU
282,987 significantly decreased OGD-induced cell death (B). However, this protection
was not observed in α7nAChR-KO neurons (C). Results are presented as mean +/- SEM;
data were analyzed and compared by one-way ANOVA and Tukey’s post hoc test. (n=4).
* or different letters above the bars indicate significant difference (P<0.05), whereas bars
denoted with the same letter are not significantly different (P>0.05).
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3.4 STI1 activates ALK2 receptors
Previous experiments have shown that STI1 can also modulate signalling
pathways independent of α7nAChRs in astrocytes (Arantes et al., 2009), peripheral
neurons (Santos et al., 2013), and cancer cells (Tsai et al., 2012). To further test whether
other signalling pathways can be activated by STI1 in hippocampal neurons, we focused
on ALK2, a poorly studied receptor in the brain. Expression data obtained from the Allen
Brain Atlas indicate selective expression of ALK2 receptors in the hippocampus (Figure
9A). Staining of mouse hippocampal neurons for the ALK2 receptor shows membrane
expression in NeuN labeled neurons (Figure 9B).
To determine the potential involvement of the ALK2 receptor in STI1-mediated
neuronal protection against OGD, wild-type mouse hippocampal neurons were treated
with variable concentrations of the ALK2 antagonist LDN 193198 and 1μM of
recombinant STI1 prior to exposure to OGD for 1 hour followed by 24 hours of
reperfusion. Our results show that inhibition of the ALK2 receptor prevented the effect of
STI1 against OGD (Figure 10; P<0.05), suggesting the potential involvement of ALK2
receptors.
To further test the possibility that activation of ALK2 receptors can modulate cell
death in response to ischemia-reperfusion we used the ALK2 agonist BMP-4. Treatment
of neurons with variable concentrations of BMP-4 significantly decreased cell death
induced by ischemia-reperfusion (Figure 11; P<0.05).
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Figure 9: Expression of ALK2 in primary cultured wild-type hippocampal neurons.
(A) The Allen Developing Mouse Brain Atlas image showing in situ hybridization for the
acvr1 gene (ALK2) in a mouse brain sagittal section. Warmer colours indicate higher
gene expression. (B) Wild-type mouse E17 primary hippocampal neurons after 7 days in
culture were stained with nuclear marker Hoechst (blue), mature neuronal marker NeuN
(green), and ALK2 (red). Composite image shows ALK2 and NeuN colocalization.
ALK2 is enriched in the cell membrane.
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Figure 10: Inhibition of the ALK2 receptor prevented the effects of STI against
OGD. Wild-type hippocampal neurons were treated with LDN 193189 (5-200nM) and/or
recombinant STI1 (1μM, 30 minutes) and then subjected to 1 hour OGD. Staurosporine
(200nM) was also used as a positive control. (A) Representative images obtained by
confocal microscopy after 24 hours of reperfusion. (B) Cell death was quantified as
percentage of total cells that were dead using Calcein-AM (live, green) and Ethidium
homodimer-1 (dead, red) dyes. Treatment of neurons with STI1 significantly decreased
cell death by OGD, an effect not observed when neurons were treated with LDN 193189
in which cell death increased in a dose-dependent manner (P<0.05). Results are presented
as mean +/- SEM; data were analyzed and compared by one-way ANOVA and Tukey’s
post hoc test. (n=8). Different letters above the bars indicate significant differences
(P<0.05), whereas bars denoted with the same letter are not significantly different
(P>0.05).
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Figure 11: Treatment of wild-type hippocampal neurons with BMP-4 significantly
decreased cell death due to OGD treatment. Wild-type hippocampal neurons were
treated with recombinant STI1 (1μM) and BMP-4 (10-500ng/mL, 30 minutes) and then
subjected to 1 hour OGD. (A) Representative images obtained by confocal microscopy
after 24 hours of reperfusion. (B) Cell death was quantified as percentage of total cells
that were dead using calcein-AM (Live, green) and ethidium homodimer-1 (dead, red)
dyes. Treatment of neurons with 10ng/mL of BMP-4 for 30 minutes prior to 1 hour OGD
significantly decreased cell death compared to neurons that were not treated with BMP-4.
At 50ng/mL of BMP-4, cell death following OGD was not significantly different from
cells treated with STI1. Results are presented as mean +/- SEM; data were analyzed and
compared by one-way ANOVA and Tukey’s post hoc test. (n=4). Different letters above
the bars indicate significant difference (P<0.05), whereas bars denoted with the same
letter are not significantly different (P>0.05).
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3.5 Treatment of neurons with BMP-4 during reperfusion
rescues neurons
The manipulations reported so far using STI1 are known to activate several
distinct and overlapping signalling pathways (Caetano et al., 2008, Zanata et al., 2002,
Tsai et al., 2012) prior to submitting neurons to ischemia-reperfusion. It would be
relevant for future pharmacological manipulations to understand whether activation of
these signalling pathways by STI1 after the onset of ischemia can also prevent neuronal
death. To answer that question, neurons were treated with STI1, PNU 282987 or BMP-4
prior to induce ischemia or just after the OGD treatment (during reperfusion). Figure 12
reveals that, as expected, activation of PrPC/α7nAChRs by STI1 (1μM) or α7nAChRs by
PNU 282987 (20μM) prevents neuronal death if neurons are treated prior to the OGD
exposure. In contrast, these two treatments were ineffective if the neurons were exposed
to them after the period of ischemia (Figure 12).
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Figure 12: PNU 282987 and STI1 only protected neurons if treated prior to OGD,
but not during reperfusion. Wild-type hippocampal neurons were treated with
recombinant STI1 (1μM) or PNU 282,987 (1-20 μM, 30 minutes) and then subjected to 1
hour OGD or treated during reperfusion. (A) Representative images obtained by confocal
microscopy after 24 hours of reperfusion. (B) Cell death was quantified as percentage of
total cells that were dead using calcein-AM (live, green) and ethidium homodimer-1
(dead, red) dyes. Treatment of neurons with STI1 or PNU 282987 decreased OGDinduced cell death, an effect not observed when these drugs were treated during the
reperfusion period (B). Results are presented as mean +/- SEM; data were analyzed and
compared by one-way ANOVA and Tukey’s post hoc test. (n=4). Different letters above
the bars indicate significant difference (P<0.05), whereas bars denoted with the same
letter are not significantly different (P>0.05).
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Interestingly, BMP-4 (100ng/mL) was effective at protecting neurons against
OGD-induced cell death if it was used prior or after the OGD treatment (Figure 13). In
addition, prevention of neuronal death by BMP-4 was attenuated by the ALK2 selective
antagonist LDN 193189 (200nM) (Figure 13). The concentrations used in these
experiments were established as the minimum concentration for the maximum effect on
cell death following OGD-reperfusion observed in the previous experiments. That is, we
found that the level of cell death observed in STI1-treated neurons that received 200nM
of LDN 193189 was similar to level of cell death observed in neurons submitted to OGD
that did not receive STI1 (Figure 10B). For BMP-4, we found that with treatment of
neurons with 100ng/mL was able to decrease cell death following OGD to a level not
significantly different to cell death observed in neurons not submitted to OGD, or STI1
treated neurons submitted to OGD (Figure 11). Thus, we used these concentrations in our
experiments with treatments during reperfusion.
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Figure 13: Treatment neurons with BMP-4 during reperfusion significantly
decreased OGD-induced cell death. Wild-type hippocampal neurons were treated with
MLA (10nM), LDN 193189 (200nM), and/or BMP-4 (100ng/mL, 30minutes) and then
subjected to 1 hour OGD. (A) Representative images obtained by confocal microscopy
after 24 hours of reperfusion. (B) Cell death was quantified as percentage of total cells
that were dead using calcein-AM (Live, green) and ethidium homodimer-1 (dead, red)
dyes. Treatment of BMP-4 (100ng/mL) either before OGD or during reperfusion
significantly reduced cell death. Treatment of either LDN 193189 or MLA prior to OGD
decreased protection. Results are presented as mean +/- SEM; data were analyzed and
compared by one-way ANOVA and Tukey’s post hoc test. (n=4). Different letters above
the bars indicate significant difference (P<0.05), whereas bars denoted with the same
letter are not significantly different (P>0.05).
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We have shown that neuroprotection by STI1 depends on PrPC (Figure 5). We
then tested whether neuroprotection by BMP-4 and PNU 282,987 bypasses the PrPCdependent step activated by STI1 or if it also require PrPC for preventing neuronal deathinduced by OGD. We treated wild-type and Prnp0/0 neurons with BMP-4 and PNU
282,987 and compared cell death between the two after OGD and reperfusion. In the
absence of PrPC, both BMP-4 and PNU 282,987 were still able to prevent OGD-induced
neuronal death (Figure 14). Furthermore, treatment of BMP-4 during reperfusion still
protected the neurons against OGD even in the absence of PrPC. Interestingly, in line with
a potential role of α7nAChRs after BMP-4 treatment, MLA or absence of α7nAChRs
completely abolished the rescue from cell death in BMP-4-treated neurons (Figure 15).
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Figure 14: Neuroprotection against OGD by PNU 282,987 and BMP4 was
independent of the PrPC. Wild-type and Prnp0/0 hippocampal neurons were treated with
recombinant STI1 (1μM), PNU 282,987 (20 μM), or BMP-4 (100ng/mL, 30minutes) and
then subjected to 1 hour OGD. BMP-4 was also treated during reperfusion in a separate
experiment group. (A) Representative images obtained by confocal microscopy after 24
hours of reperfusion. (B) Cell death was quantified as percentage of total cells that were
dead using Calcein-AM (live, green) and Ethidium homodimer-1 (dead, red) dyes. Cell
death following OGD in Prnp0/0 neurons treated with STI1was significantly higher
compared to wild-type counterparts. No significant differences were found between wildtype and Prnp0/0 neurons when treated with PNU 282987 or BMP-4 prior to OGD or
during reperfusion. Results are presented as mean +/- SEM; data were analyzed and
compared by two-way ANOVA and Tukey’s post hoc test.(n=4) *P<0.05.
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Figure 15: BMP-4 protection against OGD was dependent on the α7nAChR. Wildtype and α7nAChR-KO hippocampal neurons were treated with BMP-4 (100ng/mL, 30
minutes) and then subjected to 1 hour OGD or during reperfusion. (A) Representative
images obtained by confocal microscopy after 24 hours of reperfusion. (B) Cell death
was quantified as percentage of total cells that were dead using Calcein-AM (live, green)
and Ethidium homodimer-1 (dead, red) dyes. Treatment of BMP-4 (100ng/mL) either
before OGD or during reperfusion significantly reduced cell death, an effect not observed
in α7nAChR-null neurons. Results are presented as mean +/- SEM; data were analyzed
and compared by two-way ANOVA and Tukey’s post hoc test. (n=4). Different letters
above the bars indicate significant difference (P<0.05), whereas bars denoted with the
same letter are not significantly different (P>0.05).
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4

Discussion

Current treatments for ischemic stroke are limited in efficacy, thus calling for the
development of novel therapeutics. Recent studies have identified both STI1 and PrPC as
potential targets for stroke treatment. However, the exact mechanism by which STI1PrPC protects the brain during ischemia is poorly understood. Here we demonstrated that
the STI1-PrPC neuroprotective mechanism is dependent on the α7nAChR and ALK2
receptor. Activation of the α7nAChR and ALK2 receptor by PNU 282,987 and BMP-4,
respectively, also protected neurons against OGD in a manner independent of PrPC.
Interestingly, BMP-4 protected neurons even if treated during reperfusion. The
neuroprotective signalling mechanisms of these receptors, limitations of this study, and
future directions will be discussed in the following sections.

4.1 STI1 as a neuroprotective factor
Caspase-3 is a critical mediator of apoptosis and is often activated during
programmed cell death as a protease in the cleavage of vital cellular proteins (Porter et
al., 1999). Using our Apo mouse, we were able to quantify caspase-3 activity via the CFP
technique and demonstrate that STI1 plays a vital role in cellular survival following
OGD. One of the mechanisms suggested to be responsible for neuroprotection is
activation of PKA. Previous studies have shown that activation of cAMP and its effector
PKA protects cells against TNF-α-induced apoptosis (Insel et al., 2012, Kragsted et al.,
2004). In fact, PKA activation is one of the mechanisms by which STI1-PrPC protects
against staurosporine-induced cell death (Caetano et al., 2008, Beraldo et al., 2010).
Moreover, studies have shown that inhibition of PKA activity abolished the protective
effect of PrPC activation (Lopes et al., 2005). However, unlike ERK1/2 activation by
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STI1, PKA activation does not require PrPC endocytosis (Caetano et al., 2008). The
STI1-PrPC complex may remain near the cell surface and physically interacts with the
α7nAChR to induce calcium influx and subsequent activation of PKA, thereby inducing
protection against elevated pro-apoptotic enzymes during ischemia. Here we showed that
the α7nAChR is required in neuroprotection by STI1 against OGD, supporting the model
in which α7nAChR activation by STI1-PrPC interaction leads to PKA activation and
subsequent neuroprotection against OGD. To further examine the role of PKA in
protection against OGD-induced apoptosis, future studies should determine if the
endocytosis of PrPC is required for the anti-apoptotic effects observed is this study.
Interestingly, the protective effect of STI1 was observed as early as 3 hours
following OGD. Previous studies investigating signalling pathways of STI1 have shown
that STI1 induces PrPC internalization as early as 45 minutes following treatment
(Caetano et al., 2008), with the internalization of PrPC by STI1 being a necessary step in
STI1-mediated neuritogenesis via ERK1/2 signalling. However, STI1-PrPC has also been
shown to enhance protein synthesis in neurons via PI3K-mTOR signalling (Roffe et al.,
2010). The increase in protein synthesis as evidenced by [35S]-methionine incorporation,
which occurred after only 30 minutes of incubation with STI1 (Roffe et al., 2010). The
authors suggested that the increase in protein synthesis via the interaction between PrP C
and STI1 is critical for both neuritogenesis and neuroprotection against staurosporineinduced cell death (Roffe et al., 2010). Together, the timing of STI1-mediated signalling
demonstrated by these studies align with our observations that STI1 decreases both
caspase-3 induced fluorescence and cell death as early as 3 hours following OGD. Future
studies using the Apo mouse should examine the caspase-3 activity and cell death as
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early as one or two hours following OGD to determine how quickly STI1 acts on the cell
following or even during injury. This will help identify the timing in which signalling
pathways are active when neurons are protected by STI1, and how quickly these cellular
changes can translate into protection against OGD.
STI1 has also been suggested to have cell signalling pathways independent of the
prion protein. For example, in ovarian cancer cells, secreted STI1 acts as a ligand for
ALK2 receptors, leading to cancer cell proliferation (Tsai et al., 2012). Furthermore,
STI1 has also been shown to regulate retinal proliferation independent of the prion
protein

(Arruda-Carvalho

et

al.,

2007).

However,

in

hippocampal

neurons,

neuroprotection by STI1 against OGD was determined to be dependent on the prion
protein. Our results confirm findings in previous studies in which neuroprotection by
STI1 is dependent on the activation of the PrPC-regulated signalling pathways (Lopes et
al., 2005, Lima et al., 2007, Caetano et al., 2008, Roffe et al., 2010).

4.2 Activin receptor family member ALK2 offers unique
protection against ischemia
Activin receptors have been found to play a role in many cellular functions
including facilitation of neuronal survival following ischemia (Mukerji et al., 2007).
Studies have shown that endogenous activin can protect neurons in vitro from hydrogen
peroxide free radical stress (Mukerji et al., 2007). Here we showed that ALK2 receptors
were expressed in hippocampal neurons and played a role in STI1-PrPC neuroprotection
against OGD. In ovarian cancer cells, STI1 activates ALK2, which triggers SMAD
signalling and induces cell proliferation. Interestingly, this pathway was also observed to
be up-regulated in neurons adjacent to areas of ischemia in vivo (Mukerji et al., 2007).
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Furthermore, in a separate study, SARA was found to be up-regulated following OGD in
PC12 cells (Wang et al., 2013). As described earlier, recruitment and orientation of
SMAD proteins for phosphorylation by ALK2 receptors is dependent on SARA activity
(Kitisin et al., 2007). The authors found that down-regulation of SMAD signalling by
inhibition of SARA exacerbated neuronal death during OGD. It is possible that, in
addition to PrPC, STI1 also targets ALK2 receptors and subsequent SMAD signalling in
neurons to induce neuroprotection against OGD.
However, the two signalling pathways activated by STI1 may not be mutually
exclusive, as we observed that inhibition of the ALK2 receptor completely abolished the
neuroprotective effect of STI1 against OGD. PrP C has been described as a multi-faceted
scaffolding protein and modulates a plethora of cell surface receptors. One of the
receptors modulated by the PrPC is the α7nAChR (Beraldo et al., 2010). Interestingly, our
study demonstrates that the α7nAChR is required for BMP-4 neuroprotection against
OGD. Since BMP-4 activates ALK2, and PrPC modulates the α7nAChR, it is possible
that there is cross-talk between PrPC and ALK2. The mechanisms by which PrPC protects
neurons is by activation of PKA, attenuation of excitotoxicity by modulation of NMDA
receptors, and its interactions with the α7nAChR (Chiarini et al., 2002, Zanata et al.,
2002, Lopes 2005, Houman et al., 2008, Beraldo et al., 2010). However, in experiments
with Pnrp0/0 neurons, while neuroprotection by STI1 is dependent on the PrPC, BMP-4
does not require the PrPC for neuroprotection. While it may be possible that BMP-4 is
able to activate some or all of those pathways independently of the PrP C, it is also
possible that BMP-4 may activate an entirely different set of signal cascades downstream
of PrPC. Furthermore, neuroprotection against OGD by BMP-4 was not observed in
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neurons from the α7nAChR-KO mouse line, suggesting an interaction between BMP-4
and the α7nAChR. Activation of the α7nAChR has been documented to play a role in
attenuating inflammation-induced damage following ischemia by inducing Akt
phosphorylation and inhibition of GSK-3β activity (Duris et al., 2011, Grimes and Jope,
2001). Neuroprotection by PKA activation from STI1-PrPC is also dependent on the
α7nAChR (Chiarini et al., 2002, Beraldo et al., 2010). It is possible that BMP-4 may also
use these pathways in protection against OGD. While there is no direct evidence of
interactions between BMP-4, ALK2, and the α7nAChR, future studies should examine
both Akt/GSK-3β phosphorylation and PKA activity following treatment with BMP-4.
Furthermore, future studies should also focus on the potential mechanism in which BMP4 possibly interacts with the α7nAChR to elicit a calcium influx in manner similar to
STI1-PrPC interaction.

4.3 Treatment during reperfusion
We have investigated the potential of the α7nAChR, ALK2 receptor, and PrPC in
protecting neurons from OGD. In the experiments described above, manipulation of these
receptors occurred before the 1 hour exposure to OGD. However, in practical situations,
treatments administered following ischemic insult are much more prevalent than those
administered prior to insult. In this study we showed that neither STI1 nor PNU 282,987
were able to protect the neurons if treated after OGD. Our findings with PNU 282,987
were in contrast to those of a study in which continual post-intracerebral haemorrhage
treatment with PNU 282,987 in vivo for durations ranging from 3 hours to 3 days led to
an increased number of surviving neurons when observed three days post-insult (Hijioka
et al., 2012). Although the study focused on haemorrhagic stroke, the authors suggested
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that the α7nAChR agonist protected the brain in a manner that was independent of its
anti-inflammatory properties. This was evidenced by the lack of effect of PNU 282,987
on the expansion of the hematoma as well as the edema formation (Hijioka et al., 2012).
One

explanation

was

that,

in

vivo,

α7nAChRs

are

also

expressed

by

microglia/macrophages (Suzuki et al., 2006), which may play a role in the survival of
neurons following intracerebral haemorrhage, a model that is absent in our in vitro
experiments. Another explanation for PNU 282,987 not protecting neurons when treated
during reperfusion is that compared to in vivo models, cells in vitro have been shown to
be much more vulnerable to anoxic and excitotoxic transients (Kristian et al., 1998). To
further evaluate this, a milder insult such as a 30-minute exposure to OGD should be
conducted to see if PNU 282,987 can protect neurons if treated during reperfusion.
Furthermore, since the penumbra is the primary area of interest for pharmaceutical
intervention following stroke, a milder model of OGD using 2% oxygen and 10% of the
original concentration of glucose should be used.
However, although the lack of surrounding cellular architecture and increased
vulnerability may explain why PNU 282,987 did not protect our neurons in vitro, our
results show that BMP-4 was able to decrease cell death even if used as a treatment
during reperfusion. Although we have shown that BMP-4 neuroprotection is dependent
on the α7nAChR, unlike PNU 282,987, BMP-4 may interact with other receptors and
signalling pathways in addition to the α7nAChR. In vivo studies have shown that BMP-4
has been found to play a critical role in the differentiation of NSCs into neurons,
oligodendrocytes, and astrocytes during periods of spatiotemporal development
(Abematsu et al., 2006). Recent studies have also shown that BMP-4 is highly expressed
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in astrocytes, which can be a major source of BMPs (Hu et al., 2012). In addition, STI1
has been shown to recruit BMDCs into the area of ischemia (Lee et al., 2013). The
recruitment of BMDCs, which have been suggested to play a vital role in recovery
following ischemia, may be further influenced by BMP-4 to induce differentiation into
neurons, oligodendrocytes, and astrocytes. However, this in vivo model of recovery
following ischemia does not explain how BMP-4 protected neurons in vitro when treated
during reperfusion. Regardless, future experiments should focus on treatment of BMP-4
in in vivo models of stroke, and see if it can still protect if administered post-ischemia.

4.4 Limitations and Future Directions
4.4.1

In vivo experiments
There were several limitations within our model of stroke. During stroke, many

cytotoxic effects are present in addition to the lack of oxygen and glucose. In an in vivo
model, cytotoxic effects such as ATP depletion, increase in ROS, excessive intracellular
calcium, and ion shifts (Lau et al., 2010, MacDonald et al., 2006) may be attenuated by
the glial, astrocyte, and macrophages within the architecture surrounding the neurons
(Suzuki et al., 2006, Kristian et al., 1998). However, due to time limitations and the need
to first obtain experimental data supporting the rationale for further in vivo experiments,
all experiments in this study were carried out in vitro. It would be interesting to see if the
findings from this study can be recapitulated in vivo. For example, BMP-4 can be
administered to mice following various durations of middle cerebral artery occlusion.
Neurological damage can be assessed using the Bederson scale (Bederson et al., 1986) or
measurement of infarct size. Behavioural and neuromuscular deficits can be measured
using tests such as grip strength (described in Lee et al., 2013), elevated body swing test
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(Shyu et al., 2004), and adhesive removal (described in Beraldo et al., 2013). Evaluation
of the drugs used in our study in vivo will be further characterized in future studies for
their efficacies in treatment of stroke.
Many recent advances in stroke treatment involve thrombolytics and therapeutic
strategies that target the survival of the cells directly. However, secondary injury
mechanisms involving the inflammatory cascade can be equally damaging as the initial
cytoxicity (Aronowski et al., 2005). Cellular damage following ischemic onset is
contributed to by the failure of membrane sodium/potassium ATPase pumps and
intracellular calcium accumulation (Emsley et al., 2008). However, while cytotoxic
edema develops within minutes of ischemia onset, damage due to inflammation can occur
from hours to days, spreading from the ischemic core into the surrounding ischemic
penumbra (Baron 2001). This suggests that treatments targeting the inflammatory
response can have greater success in neuroprotection relative to treatments that combat
initial cytotoxicity. Since agonists of the α7nAChR have been identified to have a potent
anti-inflammatory effect, the α7nAChR has been discussed as a potential target for
neuroprotection against haemorrhagic stroke (Duris et al., 2011, Krafft et al., 2012, Li et
al., 2013). In addition, puerarin, a major isoflavonoid derived from Gegen, has been
found to attenuate cerebral ischemia by counteracting the inflammatory response via the
α7nAChR (Liu et al., 2013). Pro-apoptotic inflammatory enzymes such as nuclear factor
kappa (NF-κB), interleukin-6 (IL6), and tumour necrosis factor-α (TNF-α) are increased
following ischemia (Liu et al., 2013, Barnes et al., 1997). Future studies in vivo should
further examine the suppression of the anti-inflammatory cascade in the STI1-PrPC-
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α7nAChR mechanism of neuroprotection by measuring the levels of these inflammatory
markers.

4.4.2

Protection beyond the hippocampus
The most common site of stroke occurs in the middle cerebral artery (MCA) that

supplies blood to the cerebrum, resulting in deficits in both motor and cognitive
functions. On the other hand, damage to the hippocampus, which is often accompanied
by amnesia, results from infarctions in the posterior cerebral artery (PCA) (Szabo et al.,
2009). Since MCA occlusions occur more often than PCA occlusions, future studies
investigating STI1-PrPC neuroprotection should also be conducted in neurons from the
cortex and the striatum, which are more commonly damaged during ischemic stroke.
In our experiments, we primarily used hippocampal neurons. Unlike PrPC and
STI1, the expression of ALK2 is relatively scarce, and more focused in the hippocampus.
Future experiments should explore if our observations in hippocampal neurons are
reflective of the rest of the brain by repeating these experiments in neurons from different
areas of the cortex, the midbrain and the hindbrain. Immunohistochemistry experiments
should also be conducted to further examine the expression of the α7nAChR and ALK2
receptors.

4.4.3

Recombinant vs. Endogenous STI1
The difference between recombinant and endogenous astrocyte-derived STI1 has

been studied previously (Caetano et al., 2008). In conditioned media from astrocytes, the
amount of endogenous STI1 was estimated to be approximately 0.5nM, and 5nM of STI1
was required to induce ERK1/2 activation. In contrast, 100 times more recombinant STI1
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(0.5μM) was required to induce the same effect. The authors proposed that the difference
in the efficacy may be attributed to improper folding of recombinant STI1, lack of posttranslational modifications, or absence of potential co-activators in the media (Caetano et
al., 2008). In our experiments, we used recombinant STI1 concentration of 1μM to induce
neuroprotection. It would be of interest in future experiments to use astrocyte-derived
endogenous STI1 and determine if there is a difference in neuroprotection against OGD,
or perhaps a protective effect of endogenous STI1 if treated during ischemia similar to
BMP-4.

4.4.4

Calcium Signalling
Previous studies have shown that STI1 induces calcium influx via the α7nAChR

(Beraldo et al., 2010). Here we have demonstrated that the neuroprotective effect of
BMP-4 against OGD is dependent on the α7nAChR, as its effects were abolished by
treatment with MLA or in α7nAChR-null neurons. Early preliminary results conducted
showed a transient increase in calcium influx when hippocampal neurons (7 DIV) were
treated with 100ng/mL of BMP-4 (data not shown). Future experiments should fully
characterize the interaction of BMP-4 and calcium influx, and more specifically its
involvement with the α7nAChR by using both pharmacological and genetic models.

4.4.5

STI1 signalling via the ALK2 receptor in neuroprotection
In ovarian cancer cells, the secreted STI1 binds to ALK2 receptors, leading to the

recruitment and phosphorylation of SMAD 1/5, subsequent translocation to the nucleus,
up-regulation of ID3 genes, and ultimately resulting in increased cell proliferation (Tsai
et al., 2012). Here we showed that ALK2 receptors are not only expressed in
hippocampal neurons, but are also necessary for neuroprotection by STI1 against OGD. It
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would be interesting to see if the STI1-ALK2 signalling in neurons also acts through the
same or a similar signalling cascade compared to ovarian cancer cells. Future studies
should conduct Western blot analysis to see if the treatment of STI1 or BMP-4 (as a
positive control) leads to an increase in Phospho-SMAD1/5 relative to total SMAD1/5.
To further elucidate the signalling mechanism of STI1 and ALK2, a recombinant STI1
deleted of amino acids 230-245, which is involved in PrPC binding, should be used. This
will allow us to determine if SMAD signalling induced by STI1 is independent from
PrPC. The Prnp0/0 mouse line can also be used to confirm these results. In ovarian cancer
cells, STI1 was also observed to interact with clathrin, and the inhibition of clathrindependent endocytosis resulted in compromised STI1-ALK2 interaction, and ultimately
decreased SMAD1/5 phosphorylation and cell proliferation (Tsai et al., 2012). In
comparison, the endocytosis of STI1-PrPC was also found to be necessary for ERK1/2
signalling (Caetano et al., 2008). It would be of interest to see if clathrin-dependent
endocytosis also plays a role in STI1/ALK2-mediated neuroprotection. Future studies
should use immunocytochemistry to determine if treatment of neurons with STI1
increases cytoplasmic ALK2 staining. Furthermore, treatment of neurons with Dynasore,
the inhibitor of dynamin-dependent endocytosis, before OGD could further elucidate the
ALK2 pathway in neuroprotection (Macia et al., 2006).

4.5 Conclusions
Both STI1 and PrPC have been suggested to play a role in endogenous
neuroprotective mechanisms during stroke. With our findings, we suggest that the
α7nAChR and the ALK2 receptor are also potential targets for stroke treatments. Future
studies should evaluate these receptors in vivo. Overall, our findings, summarized in
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Figure 16, further elucidate the molecular mechanisms and the receptors involved in
STI1-PrPC neuroprotection, which is an important step towards the development of novel
treatments for stroke.
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?

Figure 16: Schematic of the proposed model of the α7nAChR, PrPC, ALK2, and
their interaction with STI1. Extracellular STI1 has been shown to act as a ligand for the
GPI-anchored PrPC leading to calcium influx via the α7nAChR. Here we propose the role
of the ALK2 receptor in hippocampal neurons as a receptor for the STI1 leading to
neuroprotection in conjunction to PrPC. Arrow heads indicate activation, while blunt
heads indicate inhibition. Future studies should aim to elucidate the interaction between
ALK2 and α7nAChR.
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Appendices
Animal Protocol Certificate
eSirius Notification - Annual Protocol Renewal APPROVED by the AUS 2008-127::6
2008-127::6:
AUP Number: 2008-127
AUP Title: a)Elucidating the Function acetylcholine in the central and peripheral
nervous system; b)Role of the Cellular Prion Protein in physiological and pathological
conditions
Yearly Renewal Date: 03/01/2015
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2008-127 has been
approved, and will be approved for one year following the above review date.
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the
ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in
this protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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